Informing the Need for a SARS-CoV-2 Booster Based on the Immune Responses Among Young Healthy Adults to Variants Circulating in Late 2023
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae249 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Huy C Nguyen und 14 weiteren Autor:innen. Beteiligte Einrichtung: US Naval Medical Research Unit INDO PACIFIC, Science Directorate, Singapore, Singapore. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Viral, COVID-19 Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: US Bureau of Medicine and Surgery, Restore Core Basic Operational Med Research Sciences.
Abstract (Originalsprache)
Background
COVID-19 remains a global public health challenge due to new immune-evasive SARS-CoV-2 variants and heterogeneous immunity.
Methods
In this cross-sectional study, we evaluated the adaptive immune responses in US active duty personnel who completed a COVID-19 primary vaccine series and had heterogenous SARS-CoV-2 vaccination and infection histories to 3 previously dominant variants (ancestral, Delta, BA.5) and 3 circulating variants (XBB.1.5, EG.5, and BA.2.86) in late 2023. Analyses were based on the most recent exposure in terms of timing (within or beyond 12 months) and type (vaccine or infection).
Results
Significant reduction was observed in binding antibodies, neutralization antibodies, memory B cells, and CD8+ T cells against circulating variants when compared with previous variants. The reduction in antibody response was more pronounced in those whose most recent exposure was >12 months from enrollment. In contrast, the CD4+ T-cell response was largely consistent across all tested variants. The type of most recent exposure was not a significant factor in determining the magnitude of current immune responses.
Conclusions
Administration of the XBB.1.5-based booster is likely to enhance cross-reactive humoral responses against SARS-CoV-2 circulating lineages. Ongoing surveillance of immune responses to emerging variants is needed for informing vaccine composition and timing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- US Naval Medical Research Unit INDO PACIFIC, Science Directorate, Singapore, Singapore.
- Walter Reed Army Institute of Research, US Military HIV Research Program, B Cell Biology, Silver Spring.
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda.
- Naval Medical Research Command, Diagnostics Surveillance Division, Silver Spring.
- Leidos Holdings, Inc., Reston, Maryland.
ORCID-Profile: Huy C Nguyen
Förderung
- US Bureau of Medicine and Surgery
- Restore Core Basic Operational Med Research Sciences
Zitieren
APA
Nguyen, H. C., Lal, K. G., Balinsky, C. A., Hontz, R. D., Lin, J., Beye, M. J., Smith, L., Pan, L., Cheng, Y., Fox, I., Lizewski, S. E., Foo, H. S., Krebs, S. J., Sun, P., & Letizia, A. G. (2024). Informing the Need for a SARS-CoV-2 Booster Based on the Immune Responses Among Young Healthy Adults to Variants Circulating in Late 2023. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae249
Vancouver
Nguyen HC, Lal KG, Balinsky CA, Hontz RD, Lin J, Beye MJ, et al. Informing the Need for a SARS-CoV-2 Booster Based on the Immune Responses Among Young Healthy Adults to Variants Circulating in Late 2023. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae249
BibTeX
@article{Nguyen2024,
author = {Nguyen, Huy C and Lal, Kerri G and Balinsky, Corey A and Hontz, Robert D and Lin, Jin and Beye, Matthew J and Smith, Lauren and Pan, Li and Cheng, Ying and Fox, Isabella and Lizewski, Stephen E and Foo, Hayley S and Krebs, Shelly J and Sun, Peifang and Letizia, Andrew G},
title = {Informing the Need for a SARS-CoV-2 Booster Based on the Immune Responses Among Young Healthy Adults to Variants Circulating in Late 2023},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae249}
}
EUVIMED